Ocular Therapeutix Gross Profit Over Time
| OCUL Stock | USD 7.15 0.65 10.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ocular Therapeutix Performance and Ocular Therapeutix Correlation. Ocular |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 0.154 | Return On Assets | Return On Equity |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Ocular Therapeutix and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Spero Therapeutics Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | 888 K | 888 K | 888 K | 888 K | 5.1 M | 7.7 M | 15 M | 71.6 M | 59.5 M | 57.5 M | 100.4 M | 69.6 M | 53.2 M | 101.2 M | 116.4 M | 122.2 M |
| ASMB | 0.0 | 0.0 | 0.0 | 0.0 | (24 M) | (65 K) | (80.3 K) | (35.2 M) | (57.9 M) | 16 M | 79 M | 5.8 M | (498 K) | (41.7 M) | (48 M) | (45.6 M) |
| SPRO | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | 335 K | 2 M | 4 M | 4.7 M | 9.3 M | 17.1 M | 47 M | 96.4 M | 110.8 M | 116.4 M |
| ACHL | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (303.2 K) | (778 K) | (3.3 M) | (3.7 M) | (4.7 M) | (4.3 M) | (4 M) |
| TERN | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (195 K) | (394 K) | 1000 K | (1 M) | (881 K) | (792.9 K) | (753.3 K) |
| ABOS | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.4 M | (4 K) | (169 K) | (42.3 M) | (38.1 M) | (36.2 M) |
| INZY | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (217 K) | (1.1 M) | (1.2 M) | (1.3 M) | (1.2 M) | (1.2 M) |
| XFOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5 M | (672 K) | 3 M | (1.9 M) | (2 M) | (2 M) | (1.8 M) | (1.7 M) |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (24.6 M) | (37.9 M) | (22.7 M) | (23.7 M) | (16 M) | 18.6 M | 571 K | 7.4 M | 8.5 M | 9 M |
| PDSB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (98.4 K) | (98.4 K) | (176.3 K) | (246.4 K) | (49.1 K) | (57.3 K) | (51.6 K) | (54.2 K) |
| HOOK | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | 7.6 M | 11.9 M | 19.6 M | 18.4 M | 14.2 M | 16.6 M | 19.1 M | 12.4 M |
| DAWN | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (199 K) | (531 K) | (383 K) | 125.9 M | 132.2 M |
Ocular Therapeutix and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Spero Therapeutics Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Ocular Therapeutix minus its cost of goods sold. It is profit before Ocular Therapeutix operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Ocular Therapeutix | OCUL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 6.82
Check out Ocular Therapeutix Performance and Ocular Therapeutix Correlation. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Ocular Therapeutix technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.